<?xml version='1.0' encoding='utf-8'?>
<document id="30215261"><sentence text="LC-MS/MS bioanalysis of plasma 1, 14-tetradecanedioic acid and 1, 16-hexadecanedioic acid as candidate biomarkers for organic anion-transporting polypeptide mediated drug-drug interactions."><entity charOffset="31-58" id="DDI-PubMed.30215261.s1.e0" text="1, 14-tetradecanedioic acid" /><entity charOffset="63-89" id="DDI-PubMed.30215261.s1.e1" text="1, 16-hexadecanedioic acid" /><pair ddi="false" e1="DDI-PubMed.30215261.s1.e0" e2="DDI-PubMed.30215261.s1.e0" /><pair ddi="false" e1="DDI-PubMed.30215261.s1.e0" e2="DDI-PubMed.30215261.s1.e1" /></sentence><sentence text="A robust LC-MS/MS assay was developed to quantify endogenous 1, 14-tetradecanedioic acid (TDA) and 1, 16-hexadecanedioic acid (HDA) in human plasma as potential biomarkers for evaluating drug-drug interactions mediated by the hepatic drug transporters, organic anion-transporting polypeptides"><entity charOffset="61-88" id="DDI-PubMed.30215261.s2.e0" text="1, 14-tetradecanedioic acid" /><entity charOffset="90-93" id="DDI-PubMed.30215261.s2.e1" text="TDA" /><entity charOffset="99-125" id="DDI-PubMed.30215261.s2.e2" text="1, 16-hexadecanedioic acid" /><entity charOffset="127-130" id="DDI-PubMed.30215261.s2.e3" text="HDA" /><pair ddi="false" e1="DDI-PubMed.30215261.s2.e0" e2="DDI-PubMed.30215261.s2.e0" /><pair ddi="false" e1="DDI-PubMed.30215261.s2.e0" e2="DDI-PubMed.30215261.s2.e1" /><pair ddi="false" e1="DDI-PubMed.30215261.s2.e0" e2="DDI-PubMed.30215261.s2.e2" /><pair ddi="false" e1="DDI-PubMed.30215261.s2.e0" e2="DDI-PubMed.30215261.s2.e3" /><pair ddi="false" e1="DDI-PubMed.30215261.s2.e1" e2="DDI-PubMed.30215261.s2.e1" /><pair ddi="false" e1="DDI-PubMed.30215261.s2.e1" e2="DDI-PubMed.30215261.s2.e2" /><pair ddi="false" e1="DDI-PubMed.30215261.s2.e1" e2="DDI-PubMed.30215261.s2.e3" /><pair ddi="false" e1="DDI-PubMed.30215261.s2.e2" e2="DDI-PubMed.30215261.s2.e2" /><pair ddi="false" e1="DDI-PubMed.30215261.s2.e2" e2="DDI-PubMed.30215261.s2.e3" /></sentence><sentence text="" /><sentence text="This assay was validated using fit-for-purpose approach over standard curve range of 2" /><sentence text="5-1000Â nM for TDA and HDA using analyte-free charcoal-stripped human plasma as the surrogate matrix"><entity charOffset="14-16" id="DDI-PubMed.30215261.s5.e0" text="TDA" /><entity charOffset="22-24" id="DDI-PubMed.30215261.s5.e1" text="HDA" /><pair ddi="false" e1="DDI-PubMed.30215261.s5.e0" e2="DDI-PubMed.30215261.s5.e0" /><pair ddi="false" e1="DDI-PubMed.30215261.s5.e0" e2="DDI-PubMed.30215261.s5.e1" /></sentence><sentence text=" Chromatographic separation condition was successfully optimized to separate TDA from an interference peak while maintaining both analytes in neutral forms to minimize carryover issue"><entity charOffset="77-79" id="DDI-PubMed.30215261.s6.e0" text="TDA" /></sentence><sentence text="" /><sentence text="The described assay is currently applied to a clinical study for evaluating TDA/HDA as potential substitute biomarkers for drug-drug interaction studies"><entity charOffset="76-78" id="DDI-PubMed.30215261.s8.e0" text="TDA" /><entity charOffset="80-82" id="DDI-PubMed.30215261.s8.e1" text="HDA" /><pair ddi="false" e1="DDI-PubMed.30215261.s8.e0" e2="DDI-PubMed.30215261.s8.e0" /><pair ddi="false" e1="DDI-PubMed.30215261.s8.e0" e2="DDI-PubMed.30215261.s8.e1" /></sentence><sentence text="" /></document>